Related Experiment Video
Updated: Feb 20, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical
Haiyan Grady1, David Elder2, Gregory K Webster3
1Pharmaceutical Sciences, Takeda Development Center Americas Inc., One Takeda Parkway, Deerfield, Illinois 60015.
Abstract:
This article intends to summarize the current views of the IQ Consortium Dissolution Working Group, which comprises various industry companies, on the roles of dissolution testing throughout pharmaceutical product development, registration, commercialization, and beyond. Over the past 3 decades, dissolution testing has evolved from a routine and straightforward test as a component of end-product release into a comprehensive set of tools that the developer can deploy at various stages of the product life cycle. The definitions of commonly used dissolution approaches, how they relate to one another and how they may be applied in modern drug development, and life cycle management is described in this article. Specifically, this article discusses the purpose, advantages, and limitations of quality control, biorelevant, and clinically relevant dissolution methods.
More Related Videos
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Dissolution: Requirements and Profile Comparison
Bioequivalence studies: Biowaivers
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Dissolution: Compendial Testing Models I

